Hiroaki Umebayashi

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Lancet · 2008 · 797 citations

Medicine, Clinical Sciences, Pharmacotherapy +8

Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis

Norihiro Kobayashi, Shunichiro Takezaki, Ichiro Kobayashi et al. · Lara D. Veeken · 2014 · 148 citations · Full text

Medicine, Dermatology, Pathology +17

Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes

Kenji Nakagawa, Eva González‐Roca, Alejandro Souto et al. · Annals of the Rheumatic Diseases · 2013 · 125 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

Tomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi et al. · Clinical Rheumatology · 2012 · 77 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Journal of Rheumatology · 2014 · 71 citations · Full text

Medicine, Immunology, Pharmacotherapy +13